Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas

Journal of Pathology

Volumn 205, Issue 5, 2005, Pages 592-596

  Born, Martina ^a,b   Quintanilla Fend, Leticia ^a   Braselmann, Herbert ^a   Reich, Uli ^a   Richter, Manfred ^a   Hutzler, Peter ^a   Aubele, Michaela ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast carcinoma; Her2 neu; PTK6 brk; Quantitative RT PCR

Indexed keywords

ADENOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; ONCOPROTEIN; PARAFFIN; PREFOLDIN 4; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; PROTEIN TYROSINE PHOSPHATASE; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZNF217; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 17Q; CHROMOSOME 20Q; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC LINKAGE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOMES, HUMAN, PAIR 20; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; MICRODISSECTION; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 17144412880     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1720     Document Type: Article

References (26)

1. Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994; 91: 2156-2160.
2. Isola JJ, Kallioniemi OP, Chu LW, et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995; 147: 905-911.
3. Aubele M, Mattis A, Zitzelsberger H, et al. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 2000; 85 82-86.
4. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 1994; 54: 4257-4260.
5. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996; 56: 3441-3445.
6. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 144-146.
7. Zhao C, Yasui K, Lee CJ, et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003; 98: 18-23.
8. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-968.
9. Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998; 95: 8703-8708.
10. Collins C, Volik S, Kowbel D, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res 2001; 11: 1034-1042.
11. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995; 1: 1455-1461.
12. Cingoz S, Altungoz O, Canda T, Saydam S, Aksakoglu G, Sakizli M. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. Cancer Genet Cytogenet 2003; 145: 108-114.
13. Watch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Lab Invest 2001; 81: 791-801.
14. Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004; 104: 1120-1126.
15. Specht K, Richter T, Muller U, Watch A, Hofler MW. Quantitative gene expression analysis in microdissected archival tissue by real-time RT-PCR. J Mol Med 2000; 78: B27.
16. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 2003; 17: 789-795.
17. Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001; 93: 162-171.
18. Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma. (MCL): implications for pathogenesis. Blood 2003; 101: 3181-3187.
19. Xie W, Duan R, Safe S. Activation of adenosine deaminase in MCF-7 cells through IGF-estrogen receptor alpha crosstalk. J Mol Endocrinol 2001; 26: 217-228.
20. Mitchell PJ, Barker KT, Martindale JE, et al. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994; 9 2383-2390.
21. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15: 799-805.
22. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22: 4212-4220.
23. Slamon DJ. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 1990; 8: 253.
24. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002; 8: 361-367.
25. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
26. Mitchell PJ, Sara EA, Crompton MR. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 2000; 19: 4273-4282.